目的 观察匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎的临床疗效。方法 选取2015年1月-2016年1月三门峡市中心医院收治的急性支气管炎患儿82例，随机分为对照组和治疗组，每组各41例。对照组口服氨溴特罗口服液，未满8个月，2.5 mL/次；8个月~1岁，5 mL/次；2~3岁，7.5 mL/次；4~5岁，10 mL/次；6~12岁，15 mL/次，均为2次/d；治疗组在对照组的基础上口服匹多莫德分散片，0.4 g/次，2次/d。两组患儿均连续治疗7 d。比较两组患者临床疗效、临床症状体征消失时间，对比两组治疗前后IgG、IgA、IgM指标水平。结果 治疗后，对照组和治疗组的总有效率分别为92.68%和97.56%，两组总有效率比较差异具有统计学意义（P<0.05）。与对照组相比，治疗后治疗组患儿咳嗽及肺部啰音消失的更快，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患儿IgG、IgM水平明显升高，治疗组患儿IgA水平比治疗前明显升高，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后治疗组患儿IgG、IgA、IgM水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 匹多莫德联合氨溴特罗口服液治疗小儿急性支气管炎具有良好的临床疗效，症状体征改善明显，具有一定的临床推广应用价值。

Objective To observe the clinical efficacy of pidotimod combined with ambroxol and clenbuterol in treatment of children with acute bronchitis. Methods Children (82 cases) with acute bronchitis in Sanmenxia Central Hospital from January 2015 to January 2016 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution, and children less than 8 months were given 2.5 mL/time, 5 mL/time for 8 months-1 year old children, 7.5 mL/time for 2-3 years old children, 10 mL/time for 4-5 years old children, 15 mL/time for 6-12 years old children, and all of them were given twice daily. Children in the treatment group were po administered with Pidotimod Dispersible Tablets on the basis of the control group, 0.4 g/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies and clinical signs and symptoms, the disappearing time of clinical signs and symptoms, IgG, IgA, and IgM in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 92.68% and 97.56%, respectively, and there were differences between two groups (P<0.05). Compared with the control group, the disappearing time of cough symptom and pulmonary rales in the treatment group after treatment were shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, IgG and IgM in two groups was significantly increased, IgA in the treatment group was significantly increased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Pidotimod combined with ambroxol and clenbuterol has a significant clinical curative effect in treatment of children with acute bronchitis, and can obviously improve the symptoms, which has a certain clinical application value.